Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial.

MLA

Mazieres, Julien, et al. “Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 26, no. 13, July 2020, pp. 3172–81. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-19-3056.

APA

Mazieres, J., Barlesi, F., Rouquette, I., Molinier, O., Besse, B., Monnet, I., Audigier-Valette, C., Toffart, A.-C., Renault, P. A., Fraboulet, S., Hiret, S., Mennecier, B., Debieuvre, D., Westeel, V., Masson, P., Madroszyk-Flandin, A., Pichon, E., Cortot, A. B., Amour, E., … Souquet, P.-J. (2020). Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 26(13), 3172–3181. https://doi.org/10.1158/1078-0432.CCR-19-3056

Chicago

Mazieres, Julien, Fabrice Barlesi, Isabelle Rouquette, Olivier Molinier, Benjamin Besse, Isabelle Monnet, Clarisse Audigier-Valette, et al. 2020. “Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 26 (13): 3172–81. doi:10.1158/1078-0432.CCR-19-3056.